News & Insights

Jacki C. Leifer, Senior Partner, will speak during the Opening General Session at the National Association of Community Health Centers’ Policy and Issues Forum in Washington, DC next week.  On Wednesday, February [...]

Feldesman Partner Adam J. Falcone will speak at the 2025 Policy and Issues Forum hosted by the National Association of Community Health Centers. Health care leaders from across the country will attend [...]

In a brief farewell message from the Biden Administration, the U.S. Department of Justice (DOJ) reported more than $2.9 billion in federal False Claims Act (FCA) settlements and judgments during fiscal year [...]

On January 7, 2025, the Health Resources and Services Administration (HRSA) published Program Assistance Letter (PAL) 2025-01, Calendar Year 2026 Requirements for Federal Tort Claims Act (FTCA) Coverage for Health Centers and [...]

On December 18, 2024, the Health Resources and Services Administration (HRSA) issued new instructions to apply for initial designation as a “look-alike” health center. There are several significant changes, both in terms [...]

Feldesman Partner Steve Kuperberg was quoted in the 340B Report’s December 23, 2024, edition in the aftermath of a federal judge’s ruling against a 340B contract pharmacy law in West Virginia. Following [...]

As the December 23, 2024, compliance date approaches for the HIPAA Privacy Rule to Support Reproductive Health Care Privacy Final Rule (“Final Rule”), below are three areas where HIPAA covered entities, including [...]

HHS-OIG’s recently released Fall 2024 Semiannual Report to Congress highlights an aggressive enforcement landscape and increased scrutiny for recipients of HHS funds, whether those funds are received through grants, contracts, or participation [...]

In another notable False Claims Act development, a Massachusetts federal district court recently held that, when the United States intervenes in a relator’s qui tam lawsuit under the False Claims Act (“FCA”) [...]

Federally qualified health centers (FQHCs) and other federal grantees participating in the federal 340B drug discount statute face potentially devastating, practical effects on their ability to serve vulnerable patient populations from a [...]